ARCHIVES

Hearing Scheduled To Investigate ImClone’s C225 Development, Stock Trading

This article is from The Cancer Letter archive.

Vol. 28 No. 23 | June 7, 2002

Download PDF Visit The Full Archive

Related Articles

In Brief: Morgan Named Director Of UAMS Myeloma Institute

April 25, 2014

House Committee Seeks Review Of Indirect Costs Of NIH Grantees

July 25, 2013

NCI Issues Alert On Stage 2/3 Rectal Cancer Therapy

March 22, 1991

NCI Plans $40M In Grants For Cancer Outcomes Studies.

June 30, 2000

Patients Sue Milken, Cancer Centers, Over Prostate Cancer Remedy PC-Spes

February 20, 2004

Freshman Congressman Launches Drive for “Adequate” Cancer Research Funding

August 5, 1983